Dr Bauer, Professor Linderkamp, and Professor Versmold comment: Drs Wright and Goodall present blood volume and mean arterial blood pressure (MABP) measured in 31 very low birthweight infants. No relationship was found between blood volume and MABP over a blood volume range of 46-131 ml/kg. The authors measured MABP by an invasive method, whereas we determined systolic blood pressure (SBP) by an invasive method in 14 infants and by oscillometry in 29 infants. ' We observed a significant overall third order polynomial function between SBP and blood volume (r=0-54; p<0-001) due to increased SBP in infants with blood volume >100 ml/kg (59 (9) mm Hg) when compared with infants with blood volume <100 mI/kg (48 (7) mm Hg). Drs Wright and Goodall suggest that the different results of the two studies may be due to the use of oscillometry in the majority of SBP measurements. In our study, only two out of 10 infants with blood volume >100 ml/kg had their SBP measured by an invasive method. Moreover, separate analysis of the relationship between SBP and blood volume showed a significant relationship only for SBP measured by oscillometry. It Dr Archer comments: Some enlargement of the statement with respect to limiting fluid intake to not more than 140 ml/kg/24 hours is certainly helpful. That figure came from a paper in which the smallest baby was 751 g. Now, babies much smaller than this receive successful intensive care and fluid and sodium requirements, of course, have to be individualised and will, among other things, be determined by the environment in which the infant is nursed. The comments by the Hammersmith group are, therefore, relevant. However, I should point out that I was referring to prevention of symptomatic PDA in the first week of life and not treatment of the condition, nor was I recommending prolonged restriction.
Hartnoll and colleagues refer to the paper by Walther et al ' as proof that clinical assessment is insensitive in detecting symptomatic PDA. What Walther et al actually demonstrated was that Doppler echocardiography can be used as a predictor for the development of symptomatic patent ductus which is a different matter.
The brief for the paper I wrote was a practical approach to PDA in the newborn nursery of the district general hospital where echocardiography would not normally be available. Even if it were available, the assessment used by Walther et al is quite a difficult one for occasional users to master, although I do agree with Hartnoll and colleagues that neonatologists should be developing echocardiographic skills. In neonatal intensive care, consent to enter a baby into a trial is sought from the parents. They have just had a baby and their baby is critically ill. They are asked to listen to complex medical arguments which spell out the uncertainties of treatment and they are asked to make a positive decision to consent that their baby is entered into a trial. In addition, in academic units, it is likely that, given the relatively small numbers of babies receiving intensive care, each infant may be suitable for entry into more than one trial, for each of which consent must be sought. Many parents in this situation find it easier to make no decision and so their baby is not entered.
There are a number of issues here that deserve further scrutiny. Parents clearly have a right to know about their baby's care, but it is cruel to present them with a mass of complex medical information at a time when they are already frightened and confused. The neonatal paediatrician also has an obligation to act in the best interests of his or her patient and so it must be unethical to reduce the chances of a baby's entry into a randomised trial, given the advantages it is accepted that this will bring. Is there a way out of these dilemmas?
Education of the public in the concept and importance of randomised clinical trials has been advocated.3 Other options might also be considered. If a trial sets out to compare two treatment strategies, each of which is regarded as acceptable clinical practice and each of which individually might be implemented without parental consent, then it should be legitimate to randomise a baby without parental consent. An example might be a trial comparing antibiotic policies, each' of which might be used as treatment without parental consent. Such an approach would clearly be inappropriate in, for example, a trial comparing conventional versus operative treatment, as operative treatment may only be given with parental consent. This approach would avoid having to force parents to grapple with issues that would not normally be presented to them and the equally morally questionable practice of forcing parents to F231 group.bmj.com on June 16, 2017 -Published by http://fn.bmj.com/ Downloaded from make decisions about their baby that they would not normally be asked to make and at a time when they are emotionally stressed. It also restores the right of the baby to be entered into a trial, a right which is jeopardised by the common occurrence of parents opting out of positive decision making by refusing trial entry. This well recognised reluctance to make positive decisions has led to the further suggestion that for certain research studies it might be appropriate to ask parents to opt out rather than to opt in.4
A kinder, gentler approach to the care of babies and parents should extend to the area of clinical research. In the first instance the public needs to be better educated about the intentions of research. Ethics committees need to appreciate that there are different approaches to seeking consent and should consider what method is most appropriate for a given study. Finally perhaps, we might reflect that to accept that there are occasions when a requirement to obtain parental consent is not in either the baby's or the parent's best interests, is also to place the burden of consent squarely on the shoulders of those who are most able to give truly informed consent, namely the clinician and the institution's ethics committee. 'chronic lung disease' unless we are in a position to define more fully the pathological and aetiological factors. The practical difficulties relate to the fact that radiography is oflittle help in defining the pathology, lung biopsy is difficult and dangerous, and postmortem examination is of very limited applicability.
In this third paragraph Dr Barson supports the need for studies into the risks and benefits of using Intralipid in preterm infants. That is what we were attempting to do and, to reiterate our results, we were unable to demonstrate an adverse effect on the incidence of severity of chronic lung disease, of whatever aetiology, in association with the early introduction of Intralipid into a parenteral nutrition regimen.
Fourthly, Dr Barson points to the need to encourage the manufacturers of parenteral nutrition solutions to produce products likely to have a greater safety profile when infused into preterm infants. We support that view and we are hopeful that we may be able to extend our studies into that area.
